IP Library Granted Patent US 10,994,004
Granted Patent B2
US 10,994,004 · App. 16/226,518 · Granted May 4, 2021

Immunogenic compositions comprising

Inventors: Jeremy Kroll (Urbandale, IA); Mike Roof (Ames, IA)
A61K39/105A61K39/0241A61K39/0275A61K39/12C12N7/00A61K35/74A61K39/295A61K39/39A61K2039/521A61K2039/522A61K2039/525A61K2039/542A61K2039/55A61K2039/552A61K2039/55566A61K2039/70C12N2750/10034Y02A50/30Y10S424/825
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,994,004
App. No.
16/226,518
Granted
May 4, 2021
Kind
B2
Abstract

The present invention provides combination vaccines that comprise an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine. Moreover, the present invention also relates to a kit that comprises an immunological agent effective for reducing the incidence of or lessening the severity of PPE caused by L. intracellularis , and one or more immunological active components effective in treatment and/or prophylaxis of at least one further disease-causing organism for swine.

Claims (17)

1. A pharmaceutical composition comprising:

antigens consisting essentially of

a killed Lawsonia intracellularis bacterium and

a porcine circovirus antigen; and

a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is an adjuvant.

3. The pharmaceutical composition of claim 2 , wherein the adjuvant is a water-in-oil emulsion, an oil-in-water emulsion, or a water-in-oil-in-water emulsion.

4. A method for

administering to swine the pharmaceutical composition according to claim 1 .

5. The method of claim 4 , wherein the pharmaceutically acceptable carrier is an adjuvant.

6. The method of claim 5 , wherein the adjuvant is a water-in-oil emulsion, an oil-in-water emulsion, or a water-in-oil-in-water emulsion.

7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition has between 5 to 5000 micrograms of the porcine circovirus antigen.

8. The method of claim 4 , wherein the pharmaceutical composition has between 5 to 5000 micrograms of the porcine circovirus antigen.

9. The method of claim 4 , wherein the pharmaceutical composition is administered in one dose.

10. The method of claim 4 , wherein the pharmaceutical composition is administered in multiple doses.

11. The method of claim 10 , wherein a first dose of the pharmaceutical composition is administered when the swine is about 2 to about 8 weeks of age.

12. The method of claim 11 , wherein a second dose of the pharmaceutical composition is administered about 1 to 4 weeks after the first dose.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2019
From: BOEHRINGER INGELHEIM VETMEDICA, INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 050304/0549 →
MERGER Recorded May 22, 2019
From: BOEHRINGER INGELHEIM VETMEDICA, INC.
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 049257/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2019
From: KROLL, JEREMY; ROOF, MIKE
To: BOEHRINGER INGELHEIM VETMEDICA, INC.
Reel/Frame 047939/0518 →
Continuity (5)
Continuation 15251308 · Aug 30, 2016
Division 14447694 · Jul 31, 2014
Continuation 11374350 · Mar 13, 2006
Provisional Application 60661352 · Mar 14, 2005
Related Publication 20190117755A1 · Apr 25, 2019